Ann: ATL1103 Higher Dose Study-ANP.AX, page-5

Guys this is just wrong

You all know where i stand with regards to this board and no matter what My 2mill votes are going against at this years AGM

You guys have been around here long enough to know that this study was just meant to be a 4 pers add on study, to the 1103Ph2 trial so that the higher dosage 600mg could be used going forward into the Ph3 trials.

These results confirm this drug is succesful to this stage in treating patients with acromegaly and no adverse affects have been noted ( none that could not be normalised anyway )

This is great news for the pipeline and should be treated as such and not dragged down to the level of MDs wages etc etc

Keep that end of things seperate and use your voice where it is needed in the vote at the AGM

Today is a fantastic result for ANP pipeline wise once more, its just a pity that such an excellent result has been put to the sword yet again because of this boards inability to attract investor $$ @ market

I just wonder where the AGM and annual report notice has gotten to

Will Bill Goolsbee step in as the new chairman of ANP ( food for thought )

enough from me